NuSep licences gels
Wednesday, 17 September, 2008
NuSep [ASX: NSP] will accept an offer to license its electrophoresis gel business.
The third party had offered to acquire NuSep's gels business outright or to license the technology.
It was decided that licensing the technology would provide the best return for shareholders, the company said.
The licensing deal should give NuSep enough money to fund this commercialisation of its MF10 and SpermSep separation instruments without any additional fund-raising, and will likely generate an ongoing royalty fee.
NuSep also supplies research grade biological products such as human IgG and albumin.
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
